Original Article

Molecular profiling analysis for colorectal cancer patients with Pi-Xu or Shi-Re syndrome

Xinbing Sui a,b,c,1, Yong Guo d,1, Wei Ni a, Haiyan Jin e, Haoming Lin f,*, Tian Xie a,b,c,*

a Department of Medical Oncology, Holistic Integrative Oncology Institutes and Holistic Integrative Cancer Center of Traditional Chinese and Western Medicine, the Affiliated Hospital of Hangzhou Normal University, College of Medicine, Hangzhou Normal University, Hangzhou, Zhejiang, China
b Department of Cancer Pharmacology, Holistic Integrative Pharmacy Institutes, College of Medicine, Hangzhou Normal University, Hangzhou, Zhejiang, China
c Key Laboratory of Elemene Class Anti-cancer Chinese Medicine of Zhejiang Province and Engineering Laboratory of Development and Application of Traditional Chinese Medicine from Zhejiang Province, Hangzhou Normal University, Hangzhou, Zhejiang, China
d Department of Medical Oncology, The First Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou, Zhejiang, China
e Department of Anesthesiology, The Children’s Hospital, School of Medicine, Key Laboratory of Reproductive Genetics, Ministry of Education, Zhejiang University, Hangzhou, Zhejiang Province, China
f Department of Cancer Pharmacology, Holistic Integrative Pharmacy Institutes, College of Medicine, Hangzhou Normal University, Hangzhou, Zhejiang, China
1 These authors contributed equally to this work.

A R T I C L E   I N F O

Article history:
Received 15 August 2018
Received in revised form 1 November 2018
Accepted 8 November 2018
Available online 24 November 2018

Keywords:
Molecular profiling
Colorectal cancer
Traditional Chinese medicine
ZHENG

A B S T R A C T

Background: Traditional Chinese medicine (TCM) syndromes (ZHENG in Chinese) constitute the basis of understanding the disorders of patients and guiding the use of the Chinese herbs. Colorectal cancer is divided into various subtypes mainly according to the ZHENG identification.

Objective: We aimed to determine the molecular basis underlying Pi-Xu (spleen deficiency) and Shi-Re (dampness-heat) ZHENG that are commonly found in colorectal cancer patients.

Methods: About 80 colorectal cancer patients, including 47 Pi-Xu ZHENG and 33 Shi-Re ZHENG were enrolled. Blood and tissue samples of these patients were available for protein and mRNA expression. The protein expression was determined by Immunohistochemistry (IHC) staining and mRNA profiling was detected by expression microarray. Furthermore, mRNA fold change was evaluated by qRT-PCR.

Results: The colorectal cancer patients with Shi-Re ZHENG had a poor prognosis, compared with Pi-Xu ZHENG (95% CI: 0.05–0.33; p < 0.0001). Moreover, there was a significant difference in protein expression levels (especially for mutant TP53, PCNA, PD-L1 and Ki-67) among Pi-Xu and Shi-Re ZHENG (p < 0.01). Meanwhile, mRNA expression (especially for wild type TP53, KDM6A, PCNA, PD-L1, Ki-67, CCL-2, IL-1α and COX-2) was also remarkably different between Pi-Xu and Shi-Re groups (p < 0.01).

Conclusion: Our results suggest that Shi-Re ZHENG conditions may contribute to poor overall survival in patients with colorectal cancer. Compared with Pi-Xu ZHENG, high expression of mutant TP53, PCNA, PD-L1, Ki-67, CCL-2, IL-1α and COX-2 may serve as potential biomarkers for diagnosis and prognosis of colorectal cancer patients displayed Shi-Re ZHENG.

© 2018 Korea Institute of Oriental Medicine. Publishing services by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

1. Introduction

Colorectal cancer (CRC) is the third most commonly diagnosed cancer and the third leading cause of death in cancer patients around the world. However, mortality associated with a CRC diagnosis has declined progressively in the past decades, which may be attributed to cancer screening programs, improved surgical techniques and the availability of more-effective therapeutic strategies for early-stage and advanced-stage disease. After curative treatment, however, 30% of patients with stages I–III and up to 65% of patients with stage IV CRC develop recurrent disease. Therefore, identifying efficient prognostic factors is urgently needed to enable the stratification of patients with CRC into different prognostic subgroups and subsequently improve outcomes after cancer recurrence.

Traditional Chinese Medicine (TCM), a form of complementary medicine that emphasizes bringing the patient’s body, mind,
and spirit into harmony, has been widely used for treatment of tumor patients including CRC in China. TCM rests squarely on ZHENG (syndrome differentiation) diagnosis, a process of analyzing and synthesizing data collected through four combined diagnostic methods: WANG (inspection), WEN (falling-rising tone, auscultation, and olfaction), WEN (falling tone, inquiry), and QIE (palpation).<sup>5</sup> Pi-Xu (spleen deficiency) and Shi-Re (dampness-heat) are two common ZHENG in CRC patients.<sup>5</sup> However, the impacts of these two patterns of ZHENG differentiation on colorectal cancer prognosis and their molecular basis are poorly understood.

The association between different ZHENG in the prognosis or biological characteristics of CRC has never been explored. Here, we for the first time showed that the colorectal cancer patients with Shi-Re ZHENG had a poor prognosis, compared with Pi-Xu ZHENG. Therefore, we demonstrated that there was a significant difference in protein and mRNA expression levels (especially for mutant TP53, PCNA, PD-L1, and Ki-67) among Pi-Xu and Shi-Re ZHENG, which could serve as potential biomarkers for diagnosis and prognosis of colorectal cancer patients displayed Shi-Re ZHENG.

2. Methods

2.1. Study subjects

This research protocol (No. 2018-0012) was approved by the local medical ethics committee of Hangzhou Normal University, based on the Declaration of Helsinki. A total of 80 CRC patients who underwent surgery were consecutively recruited from January 2012 to July 2017 in Hangzhou, Zhejiang, China. All subjects were genetically unrelated ethnic Han Chinese.

2.2. Diagnostic criteria

Diagnoses of all of the patients were confirmed by pathology. Trained interviewers used a uniform questionnaire to collect the TCM diagnostic information from the participants, namely, demographic factors such as age and gender, and known risk factors for CRC (including drinking, diet habit, individual disease history, marriage, and birth history). The standard criteria used for classification of CRC ZHENG were as described previously.<sup>6</sup> Since many factors may affect the formation of TCM syndromes, more than one TCM syndrome was observed in the majority of patients. To ensure a uniform and standard CRC ZHENG, the most significant TCM syndromes functioned as units, which were worked out concurrently by two TCM clinical experts.

2.3. Inclusion criteria

Advanced colorectal cancer patients meet criterions of western medicine and TCM and the following characteristics were included in the study: (a) aged between 18 and 80 years, (b) Han Chinese ethnicity, (c) newly histopathologically diagnosed with primary CRC, (d) lack of previous malignant tumors in other organs, (e) had not had antitumor therapy before recruitment, including chemotherapy and radiotherapy, and (f) did not have severe heart failure, pulmonary insufficiency, or kidney disease.

2.4. Exclusion criteria

Patients with jejunum tumor, appendix tumor, colorectal adenoma, E. stromal tumor, large intestine malignant melanoma, and large intestine leiomyosarcoma and cases without pathological diagnosis and completed data were excluded. Patients who received pre-operative chemotherapy were excluded.

2.5. CRC sample preparation

CRC tissue samples were obtained from operation, and serum samples were purified through centrifugation of blood (3000 rpm, 10 min). Supernatant was collected and stored at –80°C until further analysis. Serum levels of embryonic antigen (CEA) and lactate dehydrogenase (LDH) were determined at the time of examination in our biochemical laboratory. Serum mRNA expression profiles were detected.

2.6. Antibodies

p53 antibody (DO-1): sc-126 was obtained from Santa Cruz Biotechnology (Santa Cruz, CA, USA). PD-L1 (E1L3N®) (#13684) and Ki-67 (BDS) (#9449) antibody were obtained from Cell Signaling (Beverly, MA, USA). Anti-PCNA antibody (ab29) was obtained from Abcam.

2.7. Immunohistochemistry staining

The ChemMate EnVision Detection Kit (DAKO, Carpinteria, CA, USA) was used for immunohistochemistry according to company’s recommended procedure. Briefly, after being deparaffinized and hydrated, the paraffin-embedded sections were placed in 0.01M sodium citrate buffer (pH 6.0), and subjected to pressure cooker treatment for 2 minutes at full pressure with a domestic pressure cooker. After cooling to room temperature, the slides were rinsed with Tris buffered saline (0.05 M Tris/0.15 M NaCl, pH 7.6). The endogenous peroxidase activity was blocked by incubating the sections with 3% hydrogen peroxide. The sections were incubated with the primary antibody overnight at 4°C. Then, the ChemMate EnVision/HRP, Rabbit/Mouse (ENV) reagent was applied to the sections, followed by application of ChemMate DABt Chromogen included in the kit. The slides were lightly counterstained with hematoxylin. The area of positive cancer cells in each microscopic field was categorized as follows: 1+, 0% to 25%; 2+, 25% to 50%; 3+, 50% to 75% or 4+, 75% to 100%. The sum from 0% to 42% was assigned as “low expression.” The sum from 43 to 80 was assigned as “high expression.”

2.8. Gene expression profiling and data processing

Gene expression profiling was performed at the Genomic and Proteomics Core Facilities, German Cancer Research Center, Heidelberg, Germany.<sup>7</sup> A total of 200 ng RNA was analyzed by using HumanHT-12 Expression BeadChips (Illumina) according to the manufacturer’s instructions. Samples were run in chronological order in which patients received tumor surgery. Paired samples from the same patient (SAT/VAT) were processed in the same batch for most samples. Raw data were transformed by using variance-stabilizing transformation and normalized with robust spline normalization. Possible batch effects were adjusted with ComBat.<sup>8</sup> All preprocessing steps were carried out in the statistical software R 3.1.0 (w<sup>www.r-project.org</sup>) with the limma and sva packages.<sup>9,10</sup>

2.9. qRT-PCR

Total RNA was isolated using TRIzol reagent (Invitrogen, CA, USA) according to the manufacturer’s instructions. Genomic DNA was removed using gDNA Eliminator spin columns (Qiagen). Total RNA was reverse-transcribed into cDNA using the SuperScript<sup>III</sup> Reverse Transcriptase Kit (Invitrogen). Quantitative real-time PCR (qRT-PCR) analyses were performed using SYBR Green (Roche) on an ABI-7500 detector (Applied BioSystems). Relative gene expression levels were normalized to the internal control GAPDH.
Gene-specific primers were listed as follows: The primers for quantitative real time PCR (qRT-PCR) analysis were listed as follows:

KDM6A-F 5'-TGGAAACGTGCTTACCTG-3'
KDM6A-R 5'-TGCCGAATGTAACCTGAC-3'
PD-L1-F 5'-GTGGCACCCCAACTGAGA-3'
PD-L1-R 5'-AGTCCTTTCATTGGAGAGT-3'
CCL-2-F 5'-TGCTGCGAGTGTCTGGTGCA-3'
CCL-2-R 5'-GTGGTTCACGATTCCATGGA-3'
IL-1α-F 5'-GAACTGTCATGGAGGAAACC-3'
IL-1α-R 5'-TGGGATGGGGACGCAGTT-3'
Cox-2-F 5'-ATGTTGGAGTGAGTGTTCAAGTC-3'
Cox-2-R 5'-AGTCCTTTCATTGGAGGATGT-3'
GAPDH-F 5'-GCCAGCAATCTGTCTGGTGA-3'
GAPDH-R 5'-TGCCGAATGTGAACTCTGAC-3'

2.10. Statistical analyses

All data are expressed as mean ± Std. Statistical differences were measured using an unpaired two-sided Student t-test or one-way ANOVA for multiple comparisons when appropriate. The two-tailed $\chi^2$ test was used to analyze the association of protein expression with clinicopathological parameters. $p < 0.05$ was defined as statistically significant. All data analyses were conducted with GraphPad Prism Software Version 7 (GraphPad, San Diego, CA). Survival analyses were conducted using the Kaplan–Meier method and compared with a log-rank test.

3. Results

3.1. Characteristics of the Study Subjects

A total of 80 CRC patients were included in this study. Gender, age, and ZHENG distribution of subjects are shown in Table 1. However, there was no significant difference between gender, age, smoking and drinking status ($p > 0.05$).

3.2. ZHENG distribution and CRC patient prognosis

Pi-Xu and Shi-Re are two common ZHENG in CRC patients. Pi-Xu is the intrinsic weakness that means asthenia in origin. Shi-Re ZHENG refers to the excess in superficiality that represent the other side of CRC pathogenesis. Currently, the association between different ZHENG in the prognosis of CRC has never been explored. In this study, we evaluated whether different ZHENG types had an impact on CRC prognosis. As shown in Fig. 1, we found that the colorectal cancer patients with Shi-Re ZHENG had a poor overall survival, compared with Pi-Xu ZHENG (95% CI: 0.05–0.33; $p < 0.0001$).

3.3. Analysis of protein expression profiles in Pi-Xu and Shi-Re groups of CRC patients

To determine the molecular expression of CRC patients with Pi-Xu and Shi-Re ZHENG, the protein expression of TP53, PCNA, PD-L1 and Ki-67 was detected by immunohistochemistry, as well as the p53 mutation status by direct DNA sequencing. The correlations between clinicopathological signatures of the patients with CRC and protein expression are shown in Table 2. Among these patients, mutant TP53, PCNA, PD-L1 and Ki-67 were highly expressed in CRC patients with Shi-Re ZHENG, compared with Pi-Xu ZHENG ($p < 0.01$) (Fig. 2), which indicated that these protein expressions were remarkably correlated with Shi-Re ZHENG in CRC.

3.4. Analysis of mRNA expression profiles in Pi-Xu and Shi-Re groups of CRC patients

Next, we used gene expression array to examine mRNA expression of the three blood samples of CRC from the Pi-Xu and Shi-Re groups. As shown in Fig. 3A, we found that there was a significant difference in mRNA expression among CRC from Pi-Xu and Shi-Re groups. The higher mRNA levels of wild type TP53 and KDM6A were found in Pi-Xu groups but not Shi-Re ZHENG types ($p < 0.01$). Meanwhile, the higher mRNA levels of PCNA, PD-L1, Ki-67, CCL-2, IL-1a and COX-2 were found in Shi-Re groups but not Pi-Xu ZHENG types ($p < 0.01$). We also examined the expression of KDM6A, PD-L1, CCL-2, IL-1a and COX-2 by qRT-PCR. Our results suggested that the Shi-Re group expressed the highest levels of PD-L1, CCL-2, IL-1a and COX-2 and the lowest levels of KDM6A ($p < 0.01$) (Fig. 3B–F). Therefore, some tumor-driving genes (PCNA, PD-L1 and Ki-67) and inflammatory cytokines (CCL-2, IL-1a and COX-2) were found higher

---

Table 1

Characteristics of 80 Cases of Colorectal Cancer Patients

| Different syndromes | Pi-Xu Zheng $(n=47)$ | Shi-Re Zheng $(n=33)$ | $p$-value$^1$ |
|---------------------|---------------------|----------------------|--------------|
| Gender              |                      |                      |              |
| Male                | 26 (55.32%)         | 17 (51.52%)          | 0.8212       |
| Female              | 21 (44.68%)         | 16 (48.48%)          |              |
| Age                 |                      |                      |              |
| <60                 | 20 (42.55%)         | 15 (45.45%)          | 0.8225       |
| ≥60                 | 27 (57.45%)         | 18 (54.55%)          |              |
| Smoking             |                      |                      |              |
| No                  | 23 (48.94%)         | 14 (42.42%)          | 0.6511       |
| Yes                 | 24 (51.06%)         | 19 (57.58%)          |              |
| Drinking            |                      |                      |              |
| No                  | 25 (53.19%)         | 13 (39.39%)          | 0.2607       |
| Yes                 | 22 (46.81%)         | 20 (47.62%)          |              |
| High fat diet       |                      |                      |              |
| No                  | 21 (44.68%)         | 11 (33.33%)          | 0.359        |
| Yes                 | 26 (55.32%)         | 22 (66.67%)          |              |
| Family history      |                      |                      |              |
| No                  | 46 (97.87%)         | 31 (93.94%)          | 0.5658       |
| Yes                 | 1 (2.13%)           | 2 (6.06%)            |              |

$^1$ $\chi^2$ test was used.

---

Table 2

Correlation Between Clinic Pathological Background and Different Traditional Chinese Medicine Syndromes in 80 Cases of Colorectal Cancer Patients

| Different syndromes | Pi-Xu Zheng $(n=47)$ | Shi-Re Zheng $(n=33)$ | $p$-value$^*$ |
|---------------------|---------------------|----------------------|--------------|
| TP53 (mutant)       |                      |                      |              |
| High                | 12 (25.53%)         | 26 (78.79%)          |              |
| Low                 | 35 (74.47%)         | 7 (21.21%)           | $<0.001$**  |
| PCNA                |                      |                      |              |
| High                | 18 (38.30%)         | 22 (66.67%)          |              |
| Low                 | 29 (61.70%)         | 11 (33.33%)          | 0.0125**    |
| PD-                 |                      |                      |              |
| High                | 15 (31.91%)         | 25 (75.76%)          |              |
| Low                 | 32 (68.09%)         | 8 (24.24%)           | 0.0001**    |
| Ki-                 |                      |                      |              |
| High                | 15 (31.91%)         | 28 (75.76%)          |              |
| Low                 | 32 (68.09%)         | 5 (24.24%)           | 0.0001**    |

$^*$ $\chi^2$ test was used. $^*$ $p < 0.05$; $^*$ $p < 0.01$.
Fig. 2. Immunohistochemistry of TP53, PCNA, PD-L1 and Ki-67 in serial sections of CRC specimens with Pi-Xu and Shi-Re ZHENG.

Fig. 3. The molecular basis of Pi-Xu and Shi-Re ZHENG in CRC. (A) mRNA expression profiles of blood samples of CRC from the Pi-Xu and Shi-Re groups are detected by gene expression array; (B) mRNA expression levels of KDM6A, PD-L1, CCL-2, IL-1α, and COX-2 are confirmed by qRT-PCR.

expression in Shi-Re groups but not Pi-Xu ZHENG types, which indicated that the mRNA expression profiles of Shi-Re ZHENG in CRC were significantly different from other ZHENG types and the CRC patients with Shi-Re ZHENG may have a poor prognosis.

4. Discussion

TCM is a popular complementary treatment which has been widely used to improve clinical symptoms and prolong the survival rate of colorectal cancer. ZHENG, also known as TCM syndrome, is an integral and essential part of TCM theory. In TCM practice, the clinical diagnosis of ZHENG relies on the gathering of clinical information through inspection, auscultation, olfaction, inquiry, and palpation. TCM ZHENG is the basis of understanding the disorders of patients and the most essential principle that guides the prescription of Chinese herbal formulae. However, there is still not a clear understanding of ZHENG-specific molecules and their effects on CRC.

Although great progresses have been made for CRC treatment in the past few years, the overall survival of CRC is still low due to cancer development. Various signaling pathways have been implicated during the CRC carcinogenesis and tumor progression. The tumor suppressor p53 is widely known for its potential to induce cell death or cell cycle arrest and could, thereby, prevent neoplastic progression. X-linked lysine demethylase 6A (KDM6A, also known as UTX) is an epigenetic regulator that positively regulates gene expression programs associated with cell proliferation and invasion. The programmed death-1 (PD-1), a coinhibitory receptor expressed on activated T cells and B cells, plays a critical role in tumor initiation and development. The cancer patients harboring PD-1 or PD ligand 1 (PD-L1) protein expression have often a poor prognosis and clinical outcome. The proliferation-associated transcription factors (PCNA and Ki-67) and some inflammatory cytokines (CCL-2, IL-1α and COX-2) are also demonstrated to facilitate cancer cell proliferation and progression.
molecular basis. However, the validity, prognosis, and the molecular basis of ZHENG is poorly understood. Therefore, a better understanding of TCM ZHENG, as well as its potential biological basis, will greatly contribute to the clinical diagnosis and the treatment of CRC patients.

Pi-Xu (spleen deficiency) and Shi-Re (dampness-heat) are two common ZHENG in CRC patients. In this research, we evaluated the impact of these two ZHENG types on CRC prognosis and found CRC patients with Shi-Re ZHENG had a poor overall survival, compared with Pi-Xu ZHENG. To determine the possible molecular mechanisms underlying different TCM ZHENG, we used Immunohistochemistry staining, gene expression array and qRT-PCR to examine protein and mRNA expression of CRC patients from the Pi-Xu and Shi-Re groups. Our results indicated that some genes or cytokines were specifically changed in CRC patients with Shi-Re ZHENG but not other ZHENG types, including KDM6A, mutant TP53, the proliferation-associated transcription factors (PCNA and Ki-67) and some inflammatory-associated cytokines (CCL-2, IL-1a and COX-2). Our study will hopefully provide a promising approach for the diagnosis and prognosis of CRC patients with different ZHENG differentiation.

Data availability statement

All the data used to support the findings of this study are available from the corresponding author upon request.

Funding

This research was supported by grants from National Natural Science Foundation of China (grant nos. 81874380, 81672932 and 81730108), Zhejiang Provincial Natural Science Foundation of China for Distinguished Young Scholars (grant no. LR18H160001), Zhejiang Province Medical Science and Technology Project (grant no. 2017RC007), Key Project of Zhejiang Province Ministry of Science and Technology (grant no. 2015C03055), Talent Project of Zhejiang Association for Science and Technology (grant no. 2017YCGC002), Zhejiang Province Science and Technology Project of TCM (grant no. 2019ZZ016), Key Project of Hangzhou Ministry of Science and Technology (grant no. 20162013A07-20142013A63) and Zhejiang Provincial Project for the key discipline of traditional Chinese Medicine (grant no. 2017-XK-A09).

Conflicting interest

The authors declare no conflict of interest.

References

1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA: Cancer J Clin 2018;68:7–30.
2. Dienstmann R, Vermeulen L, Guinney J, Kopez S, Teijpar S, Tabernero J. Consensus molecular subtypes and the evolution of precision medicine in colorectal cancer. Nat Rev Cancer 2017;17:79–92.
3. van der Stok EP, Spaander MCM, Grunhagen DJ, Verhoef C, Kuipers EJ. Surveillance after curative treatment for colorectal cancer. Nat Rev Clin Oncol 2017;14:297–315.
4. Ling CJ, Yue XQ, Ling C. Three advantages of using traditional Chinese medicine to prevent and treat tumor. J Integr Med 2014;12:331–5.
5. Liu Z, Chen S, Cai J, Zhang E, Lan L, Zheng J, et al. Traditional Chinese medicine syndrome-related herbal prescriptions in treatment of malignant tumors. J Trad Chinese Med 2013;33:19–26.
6. Cheng CW, Kwok AO, Biaan ZX, Tse DM. The quintessence of traditional Chinese medicine: syndrome and its distribution among advanced cancer patients with constipation. Evid Based Complement Alternat Med 2012;2012:739642.
7. Eberwine J, Yeh H, Miyashiro K, Cao Y, Nair S, Fennel R, et al. Analysis of gene expression in single live neurons. Proc Natl Acad Sci USA 1992;89:3010–4.
8. Johnson WE, Li C, Rabonovich A. Adjusting batch effects in microarray expression data using empirical Bayes methods. Biostatistics 2007;8:118–27.
9. Du P, Kibbe WA, Lin SM. lumi: a pipeline for processing Illumina microarray. Bioinformatics 2008;24:1547–8.
10. Parker HS, Leek JT, Favorov AV, Considine M, Xia X, Chavan S, et al. Preserving biological heterogeneity with a permuted surrogate variable analysis for genomics batch correction. Bioinformatics 2014;30:2757–63.
11. Ji Q, Luo YQ, Wang WH, Liu X, Li Q, Su SB. Research advances in traditional Chinese medicine syndromes in cancer patients. J Integr Med 2016;14:12–21.
12. Wei HF, Zheng PY, Ji G. General methods for clinical effect assessment of traditional Chinese medicine. Zhong Xi Yi Jie He Xue Bao 2005;3:184–90.
13. Li AP. Zheng classification in Chinese medicine: syndrome and its distribution among advanced cancer patients with constipation. Evid Based Complement Alternat Med 2012;2012:739642.
14. Li H, Rokavec M, Jiang L, Horst D, Hermeting C. Antagonistic effects of p53 and HIF1A on microRNA-34a regulation of PPP1R11 and STAT3 and hypoxia-induced epithelial to mesenchymal transition in colorectal cancer cells. Gastroenterology 2017;153:505–20.
15. Kim BH, Sharma A, Dhar SS, Lee SH, Gu B, Chen CH, et al. UTX and ML1A coordinately regulate transcriptional programs for cell proliferation and invasiveness in breast cancer cells. Cancer Res 2014;74:1705–17.
16. Sui X, Ma J, Han W, Wang X, Fang Y, Li D, et al. The anticancer immune response of anti-PD-1/PD-L1 and the genetic determinants of response to anti-PD-1/PD-L1 antibodies in cancer patients. Oncotarget 2015;6:19393–404.
17. Wang H, He Z, Xia L, Zhang W, Xu L, Yue X, et al. PSM6 overexpression enhances the cell growth and viability of breast cancer cells leading to a poor prognosis. Oncol Rep 2018.
18. Sui X, Lei L, Chen L, Xie T, Li X. Inflammatory microenvironment in the initiation and progression of bladder cancer. Oncotarget 2017;8:93279–94.